 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
| «12 |
- 177 Lu PSMA-617 / Excel Diagnostics, Novartis
[VIRTUAL] Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1979;
P1, P1/2
PROs did not change over time overall or as a function of PSMA-TRT received; however, change in clinically important PROs was associated with response to treatment. Future studies should replicate and extend these findings to examine change in PROs as a potential prognostic factor for response to PSMA-TRT.
- ||||| 225Ac-J591 / Weill Cornell Medical College, AIkido Pharma
Determining dose-limiting toxicity and maximum tolerated dose of 225Ac-J591 in metastatic castration-resistant #ProstateCancer. @DrScottTagawa @WeillCornell joins @CaPsurvivorship @NUFeinbergMed to discuss data presented at #ASCO21 > https://t.co/tj3KUTLsQy @ASCO (Twitter) - Jul 7, 2021
- ||| 177 Lu PSMA-617 / Excel Diagnostics, Novartis, 225Ac-J591 / Weill Cornell Medical College, AIkido Pharma
#VJSounds | PSMA-targeted radionuclide therapy for prostate cancer @VJOncology brings you the latest updates from #ASCO21, w/ Karim Fizazi & @DrScottTagawa! Get the latest on 177Lu-PSMA-617 in VISION & 225Ac-J591 Listen on the go: 👉https://t.co/JpjadqehqU👈 #Oncology #PCSM (Twitter) - Jun 30, 2021
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
New P1/2 trial, Metastases: Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jun 30, 2021
P1/2, N=76, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- ||||| 225Ac-J591 / Weill Cornell Medical College, AIkido Pharma
Clinical, Video: VIDEO: Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC w/ @DrScottTagawa of @WeillCornell @nyphospital Watch now 👉https://t.co/KJ8eyvCKSK👈 @VJOncology @OncoAlert @ASCO #ASCO21 #PCsm #ProstateCancer #Oncology #OncoAlert (Twitter) - Jun 25, 2021
- |||| 225Ac-J591 / Weill Cornell Medical College
Clinical: Novel PSMA-targeted agent 225Ac-J591 shows early promise in mCRPC https://t.co/gwVTpabQPH #pcsm #prostatecancer #urology #urologist #PSMA @DrScottTagawa @weillcornell @nyphospital (Twitter) - Jun 21, 2021
- ||||| 225Ac-J591 / Weill Cornell Medical College
Determining dose-limiting toxicity and maximum tolerated dose of 225Ac-J591 in metastatic castration-resistant #ProstateCancer. @DrScottTagawa @WeillCornell joins @CaPsurvivorship @NUFeinbergMed to discuss data presented at #ASCO21 > https://t.co/tj3KUTLsQy @ASCO (Twitter) - Jun 8, 2021
- |||||| 225Ac-J591 / Weill Cornell Medical College
Clinical: Phase I study of 225Ac-J591 for men with #mCRPC. Presentation by @DrScottTagawa @WeillCornell. #ASCO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/NXdYEBd8Db @ASCO @nyphospital @sartor_oliver @cnsternberg @NolaBlueDoo (Twitter) - Jun 7, 2021
- ||||| 225Ac-J591 / Weill Cornell Medical College
Determining dose-limiting toxicity and maximum tolerated dose of 225Ac-J591 in metastatic castration-resistant #ProstateCancer. @DrScottTagawa @WeillCornell joins @CaPsurvivorship @NUFeinbergMed to discuss data presented at #ASCO21 > https://t.co/tj3KUTLsQy @ASCO (Twitter) - Jun 6, 2021
- || Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
New P1/2 trial, Metastases: Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 13, 2021
P1/2, N=33, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- rosopatamab tetraxetan (ATL101) / Telix, BZL, 177 Lu PSMA-617 / Excel Diagnostics, Novartis, 225Ac-J591 / Weill Cornell Medical College
[VIRTUAL] Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2804;
This is the largest analysis to-date of long-term AEs in patients who have received PSMA-TRT . Long-term effects on renal, liver, and marrow function are infrequent.
- Xofigo (radium Ra-223 dichloride) / Bayer
[VIRTUAL] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2762;
P1, P1/2
PSMA-targeted alpha-emitter 225Ac utilizing intact antibody J591 is tolerable with early evidence of clinical activity . Based upon these results, a follow up study [NCT04506567] testing multiple and fractionated dosing of 225Ac-J591 is underway.
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
Enrollment closed, Trial primary completion date, Metastases: 7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov) - Mar 4, 2021
P1, N=31, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Based upon these results, a follow up study [NCT04506567] testing multiple and fractionated dosing of 225Ac-J591 is underway. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Jan 2021
- 177 Lu PSMA-617 / RadioMedix, Excel Diagnostics, Novartis
[VIRTUAL] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_706;
P1/2
Patient reported outcomes, genomic, and immune analyses are exploratory. Enrollment began in August 2020 (NCT04506567).
- 177 Lu PSMA-617 / RadioMedix, Excel Diagnostics, Novartis, 225Ac-J591 / Weill Cornell Medical College
[VIRTUAL] Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC). () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_377;
In addition to PSA changes and other previously reported outcomes, even when low doses of radionuclide therapy as part of dose-escalation studies are included, the majority with detectable CTC counts have post-treatment CTC count decline. A significant portion of patients experience favorable CTC changes.
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
Enrollment open: Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov) - Nov 22, 2020
P1, N=18, Recruiting, Sponsor: Weill Medical College of Cornell University
A significant portion of patients experience favorable CTC changes. Not yet recruiting --> Recruiting
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
New P1 trial: Re-treatment 225Ac-J591 for mCRPC (clinicaltrials.gov) - Oct 5, 2020
P1, N=18, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
Enrollment open, Metastases: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov) - Sep 27, 2020
P1/2, N=105, Recruiting, Sponsor: Weill Medical College of Cornell University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | 225Ac-J591 / Weill Cornell Medical College
New investigator sponsored trial using $ATNM @ActiniumPharma 225AC platform initiated in August: "Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC" H/T @ej23ny cc @yatesinvesting @iamjohn_c @bob4punk @JNJNews @ScienceAtBMS https://t.co/rI1Tz6unYu (Twitter) - Sep 4, 2020
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
New P1/2 trial, Metastases: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=105, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- |||||| 225Ac-J591 / Weill Cornell Medical College
Oncolytic Virus, Video: VIDEO: PSMA-targeted alpha emitter 225Ac-J591 for mCRPC w/ @DrScottTagawa of @WeillCornell: https://t.co/VcyvrX5E5B @VJOncology @ASCO #VirtualMeeting #OncoAlert @OncoAlert #ProstateCancer #PCsm (Twitter) - Jul 3, 2020
- ||||| 225Ac-J591 / Weill Cornell Medical College
Clinical: .@DrScottTagawa outlines next steps in the development of PSMA-targeted alpha emitter 225Ac-J591 in men w/ metastatic castration-resistant #ProstateCancer (#mCRPC). https://t.co/MG6LMDspOx (CC @OBRtweets) #pcsm #clinicaltrials (Twitter) - Jun 30, 2020
- Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2886;
AR resistance mutations and amplifications appear to result in poorer outcome following PSMA-TRT both in terms of PSA decline and overall survival. Genetic sequencing may inform responses to PSMA-based therapies, and prospective genomic panel testing is ongoing.Supported by: Weill Cornell Medicine, Prostate Cancer Foundation, Department of Defense, NIH
- 225Ac-J591 / Weill Cornell Medical College
[VIRTUAL] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). (Poster Board 141) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1134;
P1
Enrollment to expansion cohort being completed. Research Funding: Weill Cornell Medicine, Other Foundation, Other Government Agency, U.S. National Institutes of Health
- |||||| 225Ac-J591 / Weill Cornell Medical College
Clinical: Exciting Ph1 data by @DrScottTagawa of @weillcornell @nyphospital at #AACR20 @AACR PSMA-targeted alpha emitter 225Ac-J591 in #mCRPC is safe and promising with 63.6% (14/22) PSA decline and 2 with response >1 yr @Panos_Vlach @nhbander @cnsternberg @DrDavidNanus (Twitter) - Apr 27, 2020
- Xtandi (enzalutamide) / Pfizer, Astellas, Zytiga (abiraterone acetate) / J&J, Xofigo (radium Ra-223 dichloride) / Bayer
[VIRTUAL] Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC) (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_122;
P1
Correlative studies are in progress and enrollment into a Simon 2-stage expansion cohort has been initiated. Clinicaltrials.gov NCT03276572
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
Trial completion date, Trial primary completion date, Metastases: 7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov) - Mar 3, 2020
P1, N=42, Recruiting, Sponsor: Weill Medical College of Cornell University
Clinicaltrials.gov NCT03276572 Trial completion date: Jul 2021 --> Jul 2024 | Trial primary completion date: Dec 2019 --> Dec 2021
- Provenge (sipuleucel-T) / Bausch Health, Xofigo (radium Ra-223 dichloride) / Bayer, docetaxel / Generic mfg.
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). (Poster Board E16) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_577;
P1
Clinical trial information: NCT03276572. Research Funding: Weill Cornell Medicine, Other Foundation, Other Government Agency, U.S. National Institutes of Health.
- Provenge (sipuleucel-T) / Bausch Health, Xofigo (radium Ra-223 dichloride) / Bayer, docetaxel / Generic mfg.
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). (Poster Board E16) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_274;
P1
Clinical trial information: NCT03276572. Research Funding: Weill Cornell Medicine, Other Foundation, Other Government Agency, U.S. National Institutes of Health.
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
Trial completion date, Metastases: 7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov) - Nov 29, 2019
P1, N=42, Recruiting, Sponsor: Weill Medical College of Cornell University
Research Funding: Weill Cornell Medicine, Other Foundation, Other Government Agency, U.S. National Institutes of Health. Trial completion date: Dec 2020 --> Jul 2021
- | Ac-225 rosopatamab tetraxetan (CONV01-?) / Dominari Holdings
Enrollment open, Metastases: 7R01CA207645-03: Phase I Trial of 225Ac-J591 in Patients With mCRPC (clinicaltrials.gov) - Oct 18, 2017
P1, N=42, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial completion date: Dec 2020 --> Jul 2021 Not yet recruiting --> Recruiting